Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study

Overview

This protocol is a randomized, double-blind, placebo-controlled clinical trial which aims to investigate the effect of denosumab on BMD in women with anorexia nervosa. The investigators hypothesize that 12 months of denosumab administration will result in an increase in bone mineral density, decrease in markers of bone resorption and improvement in bone microarchitecture in osteopenic women with anorexia nervosa compared with placebo. An optional extension study will offer subjects 12-month administration of open-label alendronate (an oral bisphosphonate) after the initial 12 month administration of denosumab or placebo. We hypothesize that 12 months of denosumab followed by 12 months of open-label alendronate will result in a greater increase in BMD compared to 12 months of placebo followed by 12 months of open-label alendronate. Within the group of women who receive sequential therapy with 12 months of denosumab followed by 12 months of alendronate, we hypothesize that BMD will be maintained between 12 and 24 months while on alendronate.

Full Title of Study: “Effects of Denosumab on Bone Mineral Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: July 22, 2021

Interventions

  • Drug: Denosumab 60 MG [Prolia]
    • Denosumab 60mg injection at baseline and 6 months
  • Drug: Placebo Injection
    • Placebo Injection at baseline and 6 months
  • Drug: Alendronate 70Mg Tab
    • Alendronate 70mg PO weekly starting at Month 12 through 24 months.

Arms, Groups and Cohorts

  • Experimental: Active Denosumab 60mg Injection
    • Denosumab 60mg injection at baseline study visit and 6 month study visit. Alendronate 70mg PO weekly starting at Month 12 through 24 months.
  • Placebo Comparator: Placebo
    • Placebo injection at baseline study visit and 6 month study visit. Alendronate 70mg PO weekly starting at Month 12 through 24 months.

Clinical Trial Outcome Measures

Primary Measures

  • Postero-anterior (PA) Lumbar Spine Bone Mineral Density by Dual-energy X-ray Absorptiometry (DXA)
    • Time Frame: 12 months (Period 1)
    • Postero-anterior (PA) lumbar spine bone mineral density was assessed by dual-energy x-ray absorptiometry (DXA). The DXA scanner used was a Hologic Horizon A (Hologic, Inc., Waltham, MA).

Secondary Measures

  • Percent Change Postero-anterior (PA) Lumbar Spine Bone Mineral Density by DXA
    • Time Frame: Baseline to 24 months
  • Percent Change Postero-anterior (PA) Lumbar Spine Bone Mineral Density by DXA
    • Time Frame: 12 months to 24 months (Period 2)

Participating in This Clinical Trial

Inclusion/Exclusion Criteria:

Inclusion Criteria:

  • Female – Age 20-60 years, skeletally mature with closed epiphyses – Anorexia nervosa or atypical anorexia nervosa defined by DSM-V diagnostic criteria – BMD T-score < -1.0 – Normal serum 25-OH vitamin D (>30 ng/mL) and calcium levels – For women of reproductive age, agree to use an effective contraceptive method. Highly effective methods of birth control include: – Combined (estrogen and progestogen) hormonal methods (pills, vaginal ring, or skin patch) – Intrauterine device (IUD) – Intraduterine hormonal-releasing system (IUS) – Surgery to tie both fallopian tubes (bilateral tubal ligation/occlusion) – Your male partner has had a vasectomy and testing shows there is no sperm in the semen – Dental check up within the past year Exclusion Criteria:

  • Any disease known to affect bone, including untreated thyroid dysfunction, Cushing's or renal failure – Subjects with a known esophageal disease cannot participate in the alendronate extension study – Any medication known to affect bone metabolism within 3 months of the study, excluding oral contraceptives or other forms of estrogen administration. Bisphosphonates must have been discontinued for at least one year before participation – Immunodeficiency or taking immunosuppressive therapy – Serum potassium <3.0 meq/L – Serum ALT >3 times upper limit of normal – eGFR of less than 30 ml/min – Hypocalcemia – Diabetes mellitus – Active substance abuse, including alcohol – History of malignancy – Paget disease of bone – Osteomalacia – Osteonecrosis of the jaw (ONJ) or risk factor for ONJ, such as invasive dental procedures (eg, tooth extraction, dental implants, oral surgery in the past 6 months), poor oral hygiene, periodontal and/or pre-existing dental disease, and current use of corticosteroids. – Planned invasive dental procedure over the next 24 months. – Known senstivity to any of the products or components to be administered during dosing or known sensitivity to mammalian cell derived drug products – Sensitivity to calcium or vitamin D supplements – Pregnant, planning to become pregnant with 7 months after the end of treatment and/or breastfeeding

Gender Eligibility: Female

Minimum Age: 20 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Massachusetts General Hospital
  • Collaborator
    • Amgen
  • Provider of Information About this Clinical Study
    • Principal Investigator: Karen Klahr Miller, MD, Professor of Medicine – Massachusetts General Hospital
  • Overall Official(s)
    • Karen K Miller, MD, Principal Investigator, Massachusetts General Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.